Omar Nadeem MD
Hematologic Oncology
Multiple Myeloma Physician Dana-Farber Cancer Institute
Join to View Full Profile
450 Brookline AveBoston, MA 02115
Dr. Nadeem is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rhode Island Hospital/Brown University HealthFellowship, Hematology and Medical Oncology, 2012 - 2015
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalResidency, Internal Medicine, 2009 - 2012
Ross University School of MedicineClass of 2009
Certifications & Licensure
FL State Medical License 2024 - Present
VT State Medical License 2024 - 2026
CT State Medical License 2022 - 2025
MA State Medical License 2015 - 2025
ME State Medical License 2022 - 2025
RI State Medical License 2012 - 2016
Clinical Trials
- DARA RVD For High Risk SMM Start of enrollment: 2021 Mar 08
- A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma Start of enrollment: 2022 Oct 27
Roles: Principal Investigator
Publications & Presentations
PubMed
- A phase 2 randomized study of modakafusp alfa as a single agent in patients with relapsed/refractory multiple myeloma.Sarah A Holstein, Shebli Atrash, Hira Mian, Meletios Athanasios Dimopoulos, Fredrik Schjesvold
Blood. 2025-04-25 - Bridging intensity is associated with impaired hematopoietic recovery following BCMA CAR-T therapy for multiple myeloma.Jan Hendrik Frenking, Xiang Zhou, Kai Rejeski, Vivien Wagner, Patrick Costello
Blood Advances. 2025-04-23 - Distress and symptom burden in patients with monoclonal gammopathy of undetermined significance and smoldering myeloma.Elizabeth K O'Donnell, Jennifer E Carroll, Jaqueline Perry, Katherine Padgett, Benjamin Harris
Blood Advances. 2025-04-22
Abstracts/Posters
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaOmar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyOmar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple MyelomaOmar Nadeem, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Press Mentions
When Is Treating a Precursor Condition Harmful?October 8th, 2024- Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
Immunotherapeutic and Targeted Approaches in Multiple MyelomaOctober 14th, 2020- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
